Carboxymethyl chitosan-mediated synthesis of hyaluronic acid-targeted graphene oxide for cancer drug delivery.

Abstract

In order to enhance the efficiency and specificity of anticancer drug delivery and realize intelligently controlled release, a new drug carrier was developed. Graphene oxide (GO) was first modified with carboxymethyl chitosan (CMC), followed by conjugation of hyaluronic acid (HA) and fluorescein isothiocyanate (FI). The resulting GO-CMC-FI-HA conjugate was characterized and used as a carrier to encapsulate the anticancer drug doxorubicin (DOX) to study in vitro release behavior. The drug loading capacity is as high as 95% and the drug release rate under tumor cell microenvironment of pH 5.8 is significantly higher than that under physiological conditions of pH 7.4. Cell uptake studies show that the GO-CMC-FI-HA/DOX complex can specifically target cancer cells, which are over-expressing CD44 receptors and effectively inhibit their growth. The above results suggest that the functionalized graphene-based material has potential applications for targeted delivery and controlled release of anticancer drugs.

• Authors: Huihui Yang, David H Bremner, Lei Tao, Heyu Li, Juan Hu, Limin Zhu
• Journal: Carbohydrate polymers (Carbohydr Polym) Vol. 135 Pg. 72-8 (Jan 01 2016) ISSN: 1879-1344 [Electronic] England
• PMID: 26453853 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2015 Elsevier Ltd. All rights reserved.

Chemical References

• Antineoplastic Agents
• Drug Carriers
• Oxides
• carboxymethyl-chitosan
• Graphite
• Doxorubicin
• Hyaluronic Acid
• Chitosan

Topics

• Antineoplastic Agents (administration & dosage, chemistry)
• Biological Transport
• Cell Survival (drug effects)
• Chitosan (analogs & derivatives, chemistry)
• Doxorubicin (administration & dosage, chemistry)
• Drug Carriers (administration & dosage, chemistry)
• Drug Liberation
• Graphite (chemistry)
• HeLa Cells
• Humans
• Hyaluronic Acid (chemistry)
• Oxides (chemistry)